Segment Reporting

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

Shire operates as one operating and reportable segment engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs.

For a more detailed description of segment disclosures about products, geographic areas and major customers, refer to Note 22, Segment Reporting, of Shire's 2016 Form 10-K.

In the periods set out below, Revenues by franchise were as follows:

	Three months ended September 30,				Nine months ended September 30,
(In millions)	2017		2016		2017		2016
Product sales by franchise
HEMOPHILIA	$	725.3	$	702.4	$	2,119.6	$	978.0
INHIBITOR THERAPIES	190.7		181.7		631.9		255.7
Hematology	916.0		884.1		2,751.5		1,233.7
IMMUNOGLOBULIN THERAPIES	605.1		472.5		1,613.9		610.7
BIO THERAPEUTICS	196.6		134.0		546.7		185.3
Immunology	801.7		606.5		2,160.6		796.0
VYVANSE	538.4		512.6		1,620.3		1,539.5
ADDERALL XR	106.0		80.5		242.3		281.1
MYDAYIS	10.2		—		25.9		—
Other Neuroscience	36.5		23.4		91.3		81.2
Neuroscience	691.1		616.5		1,979.8		1,901.8
FIRAZYR	195.5		146.3		461.4		411.3
ELAPRASE	152.9		146.7		454.5		424.3
REPLAGAL	117.2		118.9		349.0		340.5
VPRIV	89.6		87.7		257.3		259.3
CINRYZE	56.9		165.4		458.7		502.6
KALBITOR	16.0		11.1		48.3		39.2
Genetic Diseases	628.1		676.1		2,029.2		1,977.2
LIALDA/MEZAVANT	86.7		208.6		469.6		570.3
GATTEX/REVESTIVE	84.9		58.1		229.2		154.3
PENTASA	72.1		85.4		224.5		222.3
NATPARA	39.1		23.3		103.3		58.8
Other Internal Medicine	68.2		87.3		227.5		260.6
Internal Medicine	351.0		462.7		1,254.1		1,266.3
Ophthalmics	77.4		14.1		173.4		14.1
Oncology	68.5		55.4		189.3		75.7
Total Product sales	3,533.8		3,315.4		10,537.9		7,264.8
Royalties and other revenues
SENSIPAR royalties	42.8		38.7		128.1		112.2
3TC and ZEFFIX royalties	16.1		16.2		38.8		43.3
FOSRENOL royalties	14.3		13.7		35.0		34.3
ADDERALL XR royalties	7.7		4.7		33.6		15.7
Other Royalties and revenues	82.9		63.4		242.3		120.2
Total Royalties and other revenues	163.8		136.7		477.8		325.7
Total Revenues	$	3,697.6	$	3,452.1	$	11,015.7	$	7,590.5